7月2日，阿尔尼拉姆制药公司盘中上涨5.01%，报316.78美元/股，成交额6771.12万美元。
消息面上，公司近期密集推进战略合作：6月底宣布扩大与Komodo Health的战略合作，将其AI分析平台Marmot部署至客户端及更广泛的企业职能部门；此前还与Genesis Pharma将商业合作扩展至丹麦、芬兰、挪威及瑞典四国，获得RNAi疗法在北欧市场的商业化权利；6月初与Inceptive达成潜在总价值高达20亿美元的AI合作以加速RNAi疗法研发。多重利好持续释放提振市场情绪。同日生物科技板块整体走强，Moderna涨6.54%，Abivax涨9.26%，福泰制药涨4.93%，吉利德科学涨4.15%。
阿尔尼拉姆制药公司是RNA干扰（RNAi）疗法领域的领导者，通过RNAi技术选择性沉默致病基因，开发针对严重疾病的创新治疗方案。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.